Affimed Earlier Offered Data From Phase 1b Combo Study Of AFM13 With Pembrolizumab At ASH: Closed Dose-Escalation Shows Combo Well Tolerated, 3-Mo. ORR Compares Favorably To Historical ORR Of Pembrolizumab Alone